Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 immunogenicity comparison of recombinant SARS-CoV-2 vaccine (CHO cells) in children/adolescents versus adults
ChiCTR2100052955Phase 2Recruiting
- Sponsor
- Hunan Provincial Center for Disease Control and Prevention
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19), sponsored by Hunan Provincial Center for Disease Control and Prevention. Primary endpoints: SARS-CoV-2 neutralizing antibody and RBD protein binding antibody (IgG). Started Nov 2021; status: recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100052955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052955.